CLINICAL & PIPELINE·New Dosage Form Approval
Vancocin's Enduring Regulatory Journey: A Deep Dive into Dosage Form Approval and Continuous Lifecycle Management
Vancocin (application 050671) secured FDA approval for a Type 3 New Dosage Form on April 29, 1993, marking a critical market expansion. Subsequent approvals, including 12 labeling and 5 manufacturing (CMC) supplements through 2026, underscore a robust, long-term regulatory strategy. This continuous engagement impacts supply chain stability, quality assurance, and market positioning for global pharmaceutical stakeholders.
90-Day Activity